Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

NCT00642421 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Stopped Commercial reasons

Conditions

Acromegaly

Interventions

DRUG: C2L-OCT-01 PR, 10 or 20 mg
DRUG: C2L-OCT-01 PR, 20 mg

Sponsor

Ambrilia Biopharma, Inc.